Welcome to MorphoSys

Founded some 20 years ago, MorphoSys is today one of the world's leading biotechnology companies. From a pure antibody platform enterprise, MorphoSys has matured into a renowned biopharmaceutical company with a rich pipeline of future therapeutic antibody products and a sustainable dual therapeutic business model. The Company’s aim is to continue pushing the boundaries of antibody generation in the industry – to engineer the medicines of tomorrow.


Innovation Capital

A new initiative through which MorphoSys provides innovation capital to promising start-ups.


H1 2014 Report

Have a look at MorphoSys's Six Months' Report 2014



  • 19/08/2014 // MorphoSys and Emergent BioSolutions Sign License Agreement to Co-Develop and Commercialize Prostate Cancer Drug Candidate ES414

    more …

  • 28/07/2014 // MorphoSys Provides Update on the Company's Proprietary Drug Portfolio

    more …

Find more releases in the news overview


MorphoSys is interested in antibodies and biologics at late preclinical or early clinical stages.


Latest Webcast

Presentation of the management regarding the alliance with Emergent BioSolutions.